Aliases & Classifications for Preeclampsia/eclampsia 1

MalaCards integrated aliases for Preeclampsia/eclampsia 1:

Name: Preeclampsia/eclampsia 1 57 13
Preeclampsia/eclampsia, Type 1 40
Toxemia of Pregnancy 57
Pre-Eclampsia 73
Preg1 57
Pee1 57
Pee 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
majority of cases are sporadic
occurs in ~3% pregnancies in western populations
clinical manifestation ranges from mild, transient hypertension to hellp syndrome (hemolysis, elevated liver enzymes, and low platelets)


HPO:

32
preeclampsia/eclampsia 1:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Preeclampsia/eclampsia 1

OMIM : 57 Preeclampsia, which along with chronic hypertension and gestational hypertension comprise the hypertensive disorders of pregnancy, is characterized by new hypertension (blood pressure 140/90 or greater) presenting after 20 weeks' gestation with clinically relevant proteinuria. Preeclampsia is 1 of the top 4 causes of maternal mortality and morbidity worldwide (summary by Payne et al., 2011). Preeclampsia is otherwise known as gestational proteinuric hypertension (Davey and MacGillivray, 1988). A high proportion of patients with preeclampsia have glomerular endotheliosis, the unique histopathologic feature of the condition (Fisher et al., 1981). A distinct form of severe preeclampsia is characterized by hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome) (Brown et al., 2000). (189800)

MalaCards based summary : Preeclampsia/eclampsia 1, also known as preeclampsia/eclampsia, type 1, is related to pre-eclampsia and eclampsia, and has symptoms including edema and hyperemesis gravidarum. An important gene associated with Preeclampsia/eclampsia 1 is PEE1 (Preeclampsia/Eclampsia 1). The drugs Methyldopa and Calcium Carbonate have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and testes, and related phenotypes are hypertension and seizures

Related Diseases for Preeclampsia/eclampsia 1

Diseases in the Preeclampsia/eclampsia 5 family:

Preeclampsia/eclampsia 1 Preeclampsia/eclampsia 2
Preeclampsia/eclampsia 3 Preeclampsia/eclampsia 4

Diseases related to Preeclampsia/eclampsia 1 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 pre-eclampsia 30.2 NSD1 PEE1
2 eclampsia 11.1
3 thrombotic thrombocytopenic purpura 11.0
4 hepatitis 10.0
5 hepatic encephalopathy 10.0
6 encephalopathy 10.0
7 celiac disease 1 9.9
8 anosmia 9.9

Graphical network of the top 20 diseases related to Preeclampsia/eclampsia 1:



Diseases related to Preeclampsia/eclampsia 1

Symptoms & Phenotypes for Preeclampsia/eclampsia 1

Symptoms via clinical synopsis from OMIM:

57
Genitourinary Kidneys:
proteinuria

Muscle Soft Tissue:
edema

Cardiovascular Vascular:
maternal hypertension (after 20th week gestation, resolved postpartum)

Abdomen Liver:
elevated liver enzymes

Hematology:
thrombocytopenia (hellp syndrome)

Laboratory Abnormalities:
proteinuria
elevated liver enzymes

Growth Other:
intrauterine growth retardation (in fetus)

Prenatal Manifestations Maternal:
maternal hypertension (after 20th week gestation, resolved postpartum)

Neurologic Central Nervous System:
seizures (eclampsia)


Clinical features from OMIM:

189800

Human phenotypes related to Preeclampsia/eclampsia 1:

32 (show all 10)
# Description HPO Frequency HPO Source Accession
1 hypertension 32 HP:0000822
2 seizures 32 HP:0001250
3 proteinuria 32 HP:0000093
4 edema 32 HP:0000969
5 intrauterine growth retardation 32 HP:0001511
6 elevated hepatic transaminases 32 HP:0002910
7 thrombocytopenia 32 HP:0001873
8 preeclampsia 32 HP:0100602
9 eclampsia 32 HP:0100601
10 maternal hypertension 32 HP:0008071

UMLS symptoms related to Preeclampsia/eclampsia 1:


edema, hyperemesis gravidarum

Drugs & Therapeutics for Preeclampsia/eclampsia 1

Drugs for Preeclampsia/eclampsia 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 424)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4,Phase 2,Phase 1,Not Applicable 555-30-6 38853
2
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Not Applicable 471-34-1
3
Remifentanil Approved Phase 4,Phase 2,Phase 1 132875-61-7 60815
4
Amlodipine Approved Phase 4 88150-42-9 2162
5
Metformin Approved Phase 4,Phase 2,Phase 3,Not Applicable 657-24-9 14219 4091
6
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
7
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
8
Dalteparin Approved Phase 4,Phase 2,Phase 3 9005-49-6
9
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 772
10
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3 9005-49-6 772 46507594
11
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-56-6 439302 53477758
12
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6 23994
13
Ephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 299-42-3 9294
14
Oxymetazoline Approved, Investigational Phase 4,Not Applicable 1491-59-4 4636
15
Phenylephrine Approved Phase 4,Not Applicable 59-42-7 6041
16
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 90-82-4 7028
17
Labetalol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 36894-69-6 3869
18
Misoprostol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 59122-46-2 5282381
19
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7487-88-9 24083
20
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
21
Furosemide Approved, Vet_approved Phase 4,Phase 2 54-31-9 3440
22
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Not Applicable 103-90-2 1983
23
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Not Applicable 15687-27-1 3672
24
Captopril Approved Phase 4 62571-86-2 44093
25
Clonidine Approved Phase 4,Phase 1,Phase 2,Not Applicable 4205-90-7 2803
26
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
27
Insulin Aspart Approved Phase 4,Phase 3,Not Applicable 116094-23-6 16132418
28
Insulin Lispro Approved Phase 4,Not Applicable 133107-64-9
29
Glyburide Approved Phase 4,Not Applicable 10238-21-8 3488
30
Nifedipine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 21829-25-4 4485
31
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
32
Azithromycin Approved Phase 4,Phase 3,Not Applicable 83905-01-5 55185 447043
33
Warfarin Approved Phase 4 81-81-2 6691 54678486
34
Desogestrel Approved Phase 4 54024-22-5 40973
35
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
36
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 77-92-9 311
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
39
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1,Phase 2,Not Applicable 50-14-6 5280793
40
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1406-16-2
41
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 67-97-0 6221 5280795
42
Serine Approved, Nutraceutical Phase 4,Phase 3 56-45-1 5951
43 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Not Applicable
44 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Bone Density Conservation Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
46 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 692)
# Name Status NCT ID Phase Drugs
1 Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape) Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Low Dose Calcium to Prevent Preeclampsia Unknown status NCT02338687 Phase 4
3 Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia Unknown status NCT00117546 Phase 4 alpha methyldopa
4 Remifentanil for General Anesthesia in Preeclamptics Unknown status NCT00567957 Phase 4 Remifentanil;Saline
5 Viagra for the Treatment of IUGR Unknown status NCT00347867 Phase 4 Viagra administration in IUGR/PET pregnancies
6 Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation Unknown status NCT02353806 Phase 4 Amlodipine besylate
7 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
8 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
9 Treatment Approaches to Preeclampsia Completed NCT01030627 Phase 4
10 Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia Completed NCT02699827 Phase 4 Levobupivacaine hydrochloride;Magnesium sulphate;Saline 0.9%
11 Diuretics for Postpartum High Blood Pressure in Preeclampsia Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
12 Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid;Acetylsalicylic Acid
13 The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Completed NCT02891174 Phase 4 Ibuprofen;Acetaminophen
14 Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
15 A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
16 Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
17 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed NCT01972659 Phase 4 placebo;Magnesium Sulphate;sugammadex
18 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
19 Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT Completed NCT00790062 Phase 4 Oxytocin
20 Timing of Initiation of LMWH Administration in Pregnant Women With APS Completed NCT02326051 Phase 4 Enoxaparin;Enoxaparin
21 Metformin Versus Insulin in Gestational Diabetes Completed NCT01240785 Phase 4 metformin;insulin
22 Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients Completed NCT02466204 Phase 4 corifollitropin alfa;Follitropin Beta
23 Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo Completed NCT00744965 Phase 4 Glyburide;Placebo
24 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
25 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Recruiting NCT03233880 Phase 4 Azithromycin 1gm
26 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Recruiting NCT02920593 Phase 4 Vitamin D3
27 Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Recruiting NCT03164304 Phase 4 Magnesium Sulfate
28 Phenylephrine Versus Ephedrine in Pre-eclampsia Recruiting NCT02025426 Phase 4 Phenylephrine;Ephedrine
29 Early Vascular Adjustments During Hypertensive Pregnancy Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
30 Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension Recruiting NCT03449277 Phase 4 Oral Tablet
31 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Recruiting NCT01912677 Phase 4 Nifedipine;Labetalol;Methyldopa
32 Response to Anti-hypertensives in Pregnant and Postpartum Patients Recruiting NCT03506724 Phase 4 Nifedipine;Labetalol
33 ENOXAPARINE in the Prevention of Placental Insufficiency in Pregnant Women Recruiting NCT03528967 Phase 4 Enoxaparin 40 mg / 0.4 mL Prefilled Syringe;Aspirin 100 mg Oral Tablet, Enteric Coated
34 Chronotherapy With Low-dose Aspirin for Primary Prevention Recruiting NCT00725127 Phase 4 aspirin;aspirin
35 Chronic Hypertension and Pregnancy (CHAP) Project Recruiting NCT02299414 Phase 4 Anti-hypertensive therapy
36 Use of Warfarin After the First Trimester in Pregnant Women With APS Recruiting NCT02303171 Phase 4 Enoxaparin;Warfarin
37 Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology Recruiting NCT03177122 Phase 4 Myo-inositol
38 A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor Recruiting NCT02777190 Phase 4 Misoprostol
39 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Active, not recruiting NCT02911701 Phase 4 Acetaminophen;Ibuprofen
40 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
41 Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Not yet recruiting NCT03318211 Phase 4 Magnesium Sulfate
42 Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus Not yet recruiting NCT03570632 Phase 4 Metformin
43 Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients Not yet recruiting NCT03237000 Phase 4 MgSO4
44 Different Schemes of Magnesium Sulfate for Preeclampsia Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
45 Comparison of Awakening Versus Bedtime Dosing of Aspirin in Pre-Hypertension or Mild Essential Hypertension Terminated NCT00449618 Phase 4 Aspirin 100 mg;Placebo
46 Atenativ Effect on Uterine Blood Flow and Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
47 Failure Rate of GLyburide And Metformin Among Gestational Diabetics Withdrawn NCT03078725 Phase 4 Glyburide;Metformin
48 RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section Withdrawn NCT02009098 Phase 4 Cefuroxime
49 Low Dose Aspirin for the Prevention of Preeclampsia Unknown status NCT01890005 Phase 3 Aspirin;Placebo
50 PP13 and Doppler Study to Predict Preeclampsia Unknown status NCT00928213 Phase 2, Phase 3 Progesterone;Low molecular weight Heparin;No Drug

Search NIH Clinical Center for Preeclampsia/eclampsia 1

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Preeclampsia/eclampsia 1

Anatomical Context for Preeclampsia/eclampsia 1

MalaCards organs/tissues related to Preeclampsia/eclampsia 1:

41
Endothelial, Liver, Testes, Placenta, Thyroid, Ovary, Lung

Publications for Preeclampsia/eclampsia 1

Articles related to Preeclampsia/eclampsia 1:

(show all 19)
# Title Authors Year
1
A study of intravaginal misoprostol for induction of labor in toxemia of pregnancy. ( 11597613 )
2001
2
[Bilateral retinal detachment in toxemia of pregnancy]. ( 10526447 )
1999
3
[Changes in serum lipoprotein (a) levels related to hyperlipidemia during pregnancy--comparing normal pregnancy and toxemia of pregnancy]. ( 8721051 )
1996
4
Retinal pigment epithelium tear following toxemia of pregnancy. ( 7549444 )
1995
5
The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy. ( 1828053 )
1991
6
[Blood coagulation and fibrinolytic studies in patients with toxemia of pregnancy]. ( 2273312 )
1990
7
Changes in placental atrial natriuretic peptide receptors associated with severe toxemia of pregnancy. ( 2543965 )
1989
8
HLA antigens-antibodies system and its association with severe toxemia of pregnancy. ( 3973430 )
1985
9
[Ultrastructural and ultracytochemical characteristics of the terminal villi of the placenta in EPH-toxemia of pregnancy]. ( 3006644 )
1985
10
The role of placental urokinase inhibitor in toxemia of pregnancy. ( 6360225 )
1983
11
[Acute choriocapillaris occlusion and Elschnig's spots during a toxemia of pregnancy (author's transl)]. ( 7264211 )
1981
12
Case report: ruptured spleen, placental abruption and toxemia of pregnancy. Simultaneous complications of pregnancy. ( 927413 )
1977
13
Alkaline phosphatase activity in dialysed urine samples from patients with normal pregnancy, toxemia of pregnancy and chronic pyelonephritis. ( 5720439 )
1968
14
CHORIOANGIOMA AND TOXEMIA OF PREGNANCY. ( 14258033 )
1965
15
THE PATHOGENIC ROLE OF FIBRIN DEPOSITION IN THE GLOMERULAR LESIONS OF TOXEMIA OF PREGNANCY. ( 14078004 )
1963
16
Effect of intravenous procaine on anuria and oliguria associated with the toxemias of pregnancy. ( 13163491 )
1954
17
Retinal changes in the toxemias of pregnancy. I. History, vomiting of pregnancy, mild and severe pre-eclampsia, and eclampsia. ( 14885283 )
1951
18
Oliguria and anuria in toxemias of pregnancy. ( 18110648 )
1949
19
TOXEMIA OF PREGNANCY IN THE RABBIT : I. CLINICAL MANIFESTATIONS AND PATHOLOGY. ( 19870636 )
1937

Variations for Preeclampsia/eclampsia 1

ClinVar genetic disease variations for Preeclampsia/eclampsia 1:

6
(show top 50) (show all 261)
# Gene Variation Type Significance SNP ID Assembly Location
1 LOC108281140; MEGF6 CM000663.1: g.3411413_3431235dup duplication not provided GRCh38 Chromosome 1, 3494849: 3514671
2 LOC108281140; MEGF6 CM000663.1: g.3411413_3431235dup duplication not provided GRCh37 Chromosome 1, 3411413: 3431235
3 CM000663.1: g.41343608_41378076dup duplication not provided GRCh38 Chromosome 1, 40877936: 40912404
4 CM000663.1: g.41343608_41378076dup duplication not provided GRCh37 Chromosome 1, 41343608: 41378076
5 NC_000001.11: g.96970334_96988991del18658 deletion not provided GRCh38 Chromosome 1, 96970334: 96988991
6 NC_000001.11: g.96970334_96988991del18658 deletion not provided GRCh37 Chromosome 1, 97435890: 97454547
7 NC_000001.11: g.111383531_111391682del8152 deletion not provided GRCh38 Chromosome 1, 111383531: 111391682
8 NC_000001.11: g.111383531_111391682del8152 deletion not provided GRCh37 Chromosome 1, 111926153: 111934304
9 CD160; PDZK1; RNF115 NC_000001.10: g.145625979_145762959del136981 deletion not provided GRCh37 Chromosome 1, 145625979: 145762959
10 KIF26B NM_018012.4(KIF26B): c.1166+53868_1166+59172del deletion not provided GRCh38 Chromosome 1, 245473613: 245478917
11 KIF26B NM_018012.4(KIF26B): c.1166+53868_1166+59172del deletion not provided GRCh37 Chromosome 1, 245636915: 245642219
12 SOX11 NC_000002.11: g.4677905_5958997dup duplication not provided GRCh37 Chromosome 2, 4677905: 5958997
13 NC_000002.12: g.49630800_49638002del7203 deletion not provided GRCh38 Chromosome 2, 49630800: 49638002
14 NC_000002.12: g.49630800_49638002del7203 deletion not provided GRCh37 Chromosome 2, 49857938: 49865140
15 LOC730100 NR_135237.1(LOC730100): n.754-62628_754-62323del deletion not provided GRCh38 Chromosome 2, 51699461: 51699766
16 LOC730100 NR_135237.1(LOC730100): n.754-62628_754-62323del deletion not provided GRCh37 Chromosome 2, 51926599: 51926904
17 NC_000002.11: g.89427986_90240473dup duplication not provided GRCh37 Chromosome 2, 89427986: 90240473
18 NC_000002.11: g.89427986_91820358dup duplication not provided GRCh37 Chromosome 2, 89427986: 91820358
19 NC_000002.11: g.90094257_90109261del15005 deletion not provided GRCh37 Chromosome 2, 90094257: 90109261
20 REV1 CM000664.1: g.100055763_100062163dup duplication not provided GRCh38 Chromosome 2, 99439301: 99445701
21 REV1 CM000664.1: g.100055763_100062163dup duplication not provided GRCh37 Chromosome 2, 100055763: 100062163
22 LRP1B NM_018557.2(LRP1B): c.344-65793_344-61550del deletion not provided GRCh38 Chromosome 2, 141316191: 141320434
23 LRP1B NM_018557.2(LRP1B): c.344-65793_344-61550del deletion not provided GRCh37 Chromosome 2, 142073760: 142078003
24 BAZ2B; LOC643072 NM_001282805.1(MARCH7): c.-247472_-1723dup duplication not provided GRCh38 Chromosome 2, 159465277: 159711026
25 BAZ2B; LOC643072 NM_001282805.1(MARCH7): c.-247472_-1723dup duplication not provided GRCh37 Chromosome 2, 160321788: 160567537
26 ACSL3 CM000664.1: g.223798501_223823141dup duplication not provided GRCh38 Chromosome 2, 222933783: 222958423
27 ACSL3 CM000664.1: g.223798501_223823141dup duplication not provided GRCh37 Chromosome 2, 223798501: 223823141
28 TM4SF20 NM_024795.3(TM4SF20): c.-14304_183+492dup duplication not provided GRCh38 Chromosome 2, 227378594: 227393572
29 TM4SF20 NM_024795.3(TM4SF20): c.-14304_183+492dup duplication not provided GRCh37 Chromosome 2, 228243310: 228258288
30 LINC01237; LINC01238; LINC01880; LINC01881; LOC285097 NR_110592.1(LINC01238): n.972-495_131503del deletion not provided GRCh38 Chromosome 2, 241975583: 242106609
31 LINC01237; LINC01238; LINC01880; LINC01881; LOC285097 NR_110592.1(LINC01238): n.972-495_131503del deletion not provided GRCh37 Chromosome 2, 242917734: 243048760
32 ARPP21 CM000665.1: g.35826707_35902885dup duplication not provided GRCh38 Chromosome 3, 35785215: 35861393
33 ARPP21 CM000665.1: g.35826707_35902885dup duplication not provided GRCh37 Chromosome 3, 35826707: 35902885
34 CTDSPL NM_001008392.1(CTDSPL): c.80-8666_80-2299del deletion not provided GRCh38 Chromosome 3, 37938391: 37944758
35 CTDSPL NM_001008392.1(CTDSPL): c.80-8666_80-2299del deletion not provided GRCh37 Chromosome 3, 37979882: 37986249
36 SFMBT1 NM_016329.3(SFMBT1): c.-130-31770_-130-30021del deletion not provided GRCh38 Chromosome 3, 52999279: 53001028
37 SFMBT1 NM_016329.3(SFMBT1): c.-130-31770_-130-30021del deletion not provided GRCh37 Chromosome 3, 53033295: 53035044
38 NC_000003.12: g.65206172_65228858del22687 deletion not provided GRCh38 Chromosome 3, 65206172: 65228858
39 NC_000003.12: g.65206172_65228858del22687 deletion not provided GRCh37 Chromosome 3, 65191847: 65214533
40 NC_000003.12: g.65206172_65230129del23958 deletion not provided GRCh38 Chromosome 3, 65206172: 65230129
41 NC_000003.12: g.65206172_65230129del23958 deletion not provided GRCh37 Chromosome 3, 65191847: 65215804
42 NC_000003.12: g.65206172_65226921del20750 deletion not provided GRCh38 Chromosome 3, 65206172: 65226921
43 NC_000003.12: g.65206172_65226921del20750 deletion not provided GRCh37 Chromosome 3, 65191847: 65212596
44 LINC02018 NC_000003.12: g.75379524_75556006del176483 deletion not provided GRCh38 Chromosome 3, 75379524: 75556006
45 LINC02018 NC_000003.12: g.75379524_75556006del176483 deletion not provided GRCh37 Chromosome 3, 75428675: 75605157
46 FRG2C; LINC00960; LINC02018; MIR1324 NR_031714.1(MIR1324): n.-251239_47012del deletion not provided GRCh38 Chromosome 3, 75379524: 75677774
47 FRG2C; LINC00960; LINC02018; MIR1324 NR_031714.1(MIR1324): n.-251239_47012del deletion not provided GRCh37 Chromosome 3, 75428675: 75726925
48 ADGRG7; TFG CM000665.1: g.100351696_100437892dup duplication not provided GRCh38 Chromosome 3, 100632852: 100719048
49 ADGRG7; TFG CM000665.1: g.100351696_100437892dup duplication not provided GRCh37 Chromosome 3, 100351696: 100437892
50 NC_000003.12: g.149246905_149249548del2644 deletion not provided GRCh38 Chromosome 3, 149246905: 149249548

Expression for Preeclampsia/eclampsia 1

Search GEO for disease gene expression data for Preeclampsia/eclampsia 1.

Pathways for Preeclampsia/eclampsia 1

GO Terms for Preeclampsia/eclampsia 1

Sources for Preeclampsia/eclampsia 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....